Iambic Therapeutics Files for Nasdaq IPO at $16 a Share
The company is offering 9,375,000 shares under ticker IAM, with gross proceeds expected to be $150 million. Underwriters have a 30-day option.
Iambic Therapeutics filed a final prospectus for its Nasdaq initial public offering, pricing 9375000 shares at $16.00 each under the ticker “IAM.” The shares are listed on the Nasdaq Global Select Market. Gross proceeds are expected to total $150 million, and underwriters have a 30-day option.